1 / 7

XU H et al. Chin J Cardiol. 2013;41(3):205-209.

Can we protect patients undergoing percutaneous coronary intervention better ? Beneficial effects of short- and long-term trimetazidine MR therapy in patients undergoing PCI. XU H et al. Chin J Cardiol. 2013;41(3):205-209. Revascularization may cause irreversible myocardial injuries.

wes
Download Presentation

XU H et al. Chin J Cardiol. 2013;41(3):205-209.

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Can we protect patients undergoing percutaneous coronary intervention better?Beneficial effects of short- and long-term trimetazidine MR therapyin patients undergoing PCI XU H et al. Chin J Cardiol. 2013;41(3):205-209.

  2. Revascularization may cause irreversible myocardial injuries About one-third of all elective PCI procedures are associated with significant myocardial injury, which has been linked to increased subsequent mortality.

  3. Beneficial effects of trimetazidine therapy during PCI • Methods • 106 patients with unstable angina pectoris who underwent successful elective PCI • were randomly assigned to standard therapy or trimetazidine treatment • (60-mg loading dose prior to PCI followed by 20 mg tid after PCI on top of standard therapy). • Primary end point, cTnI levels, measured before and at 16-18 hours after PCI. • Secondary end points: • Left ventricular (LV) function evaluated by echocardiography • MACE (death, reinfarction, and target vessel revascularization) XU H et al. Chin J Cardiol. 2013;41(3):205-209.

  4. Beneficial effects of trimetazidine therapy during PCI Results Postprocedural cTnI levels were significantly reduced in the trimetazidine group compared with the control group (P< 0.05). -92% XU H et al. Chin J Cardiol. 2013;41(3):205-209.

  5. Beneficial effects of trimetazidine therapy during PCI Results XU H et al. Chin J Cardiol. 2013;41(3):205-209.

  6. Beneficial effects of trimetazidine therapy during PCI Conclusion Trimetazidine can reduce the post-PCI cTnI release and improve LV function after PCI in patients with unstable angina pectoris. Discussion XU H et al. Chin J Cardiol. 2013;41(3):205-209.

  7. Conclusion • About one-third of all elective PCI procedures are associated with significant myocardial injury, which has been linked to increased subsequent mortality. • Trimetazidine can effectively reduce PCI-associated myocardial damage, and has a protective effect on the myocardium. • These benefits could be linked to the mode of action of trimetazidine MR. By providing a 33% increase in cellular energy, trimetazidine MR protects cardiomyocytes against ischemia.

More Related